HealthAdvocates say women with PMOS should receive subsidised weight-loss drugs
The Polyendocrine Metabolic Ovarian Syndrome Association of Australia is calling for GLP-1 drugs to be listed on the Pharmaceutical Benefits Scheme for people with PMOS. The drugs are not specifically approved to treat the condition, though some patients receive them off-label. Advocates say the cost leaves some women unable to access them.
TThe Guardian★★★☆☆2026-10-09 23:00Original
Advocates say women with PMOS should receive subsidised weight-loss drugs
Health